Cannabis use and psychotic disorders in diverse settings in the Global South: findings from INTREPID II.
cannabis
first-onset
global mental health
psychosis
schizophrenia
Journal
Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
medline:
17
12
2023
pubmed:
24
3
2023
entrez:
23
3
2023
Statut:
ppublish
Résumé
Cannabis use has been linked to psychotic disorders but this association has been primarily observed in the Global North. This study investigates patterns of cannabis use and associations with psychoses in three Global South (regions within Latin America, Asia, Africa and Oceania) settings. Case-control study within the International Programme of Research on Psychotic Disorders (INTREPID) II conducted between May 2018 and September 2020. In each setting, we recruited over 200 individuals with an untreated psychosis and individually-matched controls (Kancheepuram India; Ibadan, Nigeria; northern Trinidad). Controls, with no past or current psychotic disorder, were individually-matched to cases by 5-year age group, sex and neighbourhood. Presence of psychotic disorder assessed using the Schedules for Clinical Assessment in Neuropsychiatry and cannabis exposure measured by the World Health Organisation Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Cases reported higher lifetime and frequent cannabis use than controls in each setting. In Trinidad, cannabis use was associated with increased odds of psychotic disorder: lifetime cannabis use (adj. OR 1.58, 95% CI 0.99-2.53); frequent cannabis use (adj. OR 1.99, 95% CI 1.10-3.60); cannabis dependency (as measured by high ASSIST score) (adj. OR 4.70, 95% CI 1.77-12.47), early age of first use (adj. OR 1.83, 95% CI 1.03-3.27). Cannabis use in the other two settings was too rare to examine associations. In line with previous studies, we found associations between cannabis use and the occurrence and age of onset of psychoses in Trinidad. These findings have implications for strategies for prevention of psychosis.
Sections du résumé
BACKGROUND
BACKGROUND
Cannabis use has been linked to psychotic disorders but this association has been primarily observed in the Global North. This study investigates patterns of cannabis use and associations with psychoses in three Global South (regions within Latin America, Asia, Africa and Oceania) settings.
METHODS
METHODS
Case-control study within the International Programme of Research on Psychotic Disorders (INTREPID) II conducted between May 2018 and September 2020. In each setting, we recruited over 200 individuals with an untreated psychosis and individually-matched controls (Kancheepuram India; Ibadan, Nigeria; northern Trinidad). Controls, with no past or current psychotic disorder, were individually-matched to cases by 5-year age group, sex and neighbourhood. Presence of psychotic disorder assessed using the Schedules for Clinical Assessment in Neuropsychiatry and cannabis exposure measured by the World Health Organisation Alcohol, Smoking and Substance Involvement Screening Test (ASSIST).
RESULTS
RESULTS
Cases reported higher lifetime and frequent cannabis use than controls in each setting. In Trinidad, cannabis use was associated with increased odds of psychotic disorder: lifetime cannabis use (adj. OR 1.58, 95% CI 0.99-2.53); frequent cannabis use (adj. OR 1.99, 95% CI 1.10-3.60); cannabis dependency (as measured by high ASSIST score) (adj. OR 4.70, 95% CI 1.77-12.47), early age of first use (adj. OR 1.83, 95% CI 1.03-3.27). Cannabis use in the other two settings was too rare to examine associations.
CONCLUSIONS
CONCLUSIONS
In line with previous studies, we found associations between cannabis use and the occurrence and age of onset of psychoses in Trinidad. These findings have implications for strategies for prevention of psychosis.
Identifiants
pubmed: 36951137
doi: 10.1017/S0033291723000399
pii: S0033291723000399
pmc: PMC10719629
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7062-7069Subventions
Organisme : Medical Research Council
ID : MR/P025927/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S003444/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/X022242/1
Pays : United Kingdom
Références
Psychol Med. 2023 Jan 16;:1-9
pubmed: 36645027
Am J Epidemiol. 2002 Aug 15;156(4):319-27
pubmed: 12181101
Schizophr Bull. 2016 Sep;42(5):1262-9
pubmed: 26884547
Lancet. 2007 Jul 28;370(9584):319-28
pubmed: 17662880
BMJ. 2002 Nov 23;325(7374):1212-3
pubmed: 12446537
Mol Psychiatry. 2018 May;23(5):1287-1292
pubmed: 28115737
Lancet Psychiatry. 2015 Mar;2(3):233-8
pubmed: 26359901
JAMA Psychiatry. 2023 Jan 1;80(1):40-48
pubmed: 36383387
Soc Psychiatry Psychiatr Epidemiol. 2015 Jun;50(6):879-93
pubmed: 25631693
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Soc Psychiatry Psychiatr Epidemiol. 2020 May;55(5):527-537
pubmed: 31796983
JAMA Psychiatry. 2020 Aug 1;77(8):777-778
pubmed: 32267480
Compr Psychiatry. 2009 Jan-Feb;50(1):13-9
pubmed: 19059508
BMJ. 2016 Feb 25;352:i969
pubmed: 26916049
Arch Gen Psychiatry. 2011 Jun;68(6):555-61
pubmed: 21300939
Br J Psychiatry. 2009 Dec;195(6):488-91
pubmed: 19949195
Psychol Med. 2021 Jun;51(8):1329-1337
pubmed: 32183927
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
JAMA Psychiatry. 2021 May 1;78(5):467-468
pubmed: 33146687
Arch Gen Psychiatry. 1991 Aug;48(8):764-70
pubmed: 1883262
Schizophr Bull. 2014 Nov;40(6):1509-17
pubmed: 24345517
Psychol Med. 2019 Jun;49(8):1378-1391
pubmed: 30282569
Nat Neurosci. 2018 Sep;21(9):1161-1170
pubmed: 30150663
Addiction. 2019 Feb;114(2):278-293
pubmed: 30276906
Addiction. 2008 Jun;103(6):1039-47
pubmed: 18373724
Eur Arch Psychiatry Clin Neurosci. 2020 Jun;270(4):403-412
pubmed: 31563981
BMJ. 2002 Nov 23;325(7374):1199
pubmed: 12446534
Int J Soc Psychiatry. 2018 Nov;64(7):690-704
pubmed: 30442059
Int J Methods Psychiatr Res. 2011 Mar;20(1):40-9
pubmed: 21499542
Psychol Med. 2017 Apr;47(5):971-980
pubmed: 27928975
Schizophr Res. 2018 Apr;194:13-17
pubmed: 28427930
Brain Sci. 2020 Feb 12;10(2):
pubmed: 32059350
Curr Opin Psychol. 2021 Apr;38:56-60
pubmed: 32828987
Schizophr Bull. 2021 Jul 8;47(4):889-895
pubmed: 33948664
BMJ Open. 2020 Jun 21;10(6):e039004
pubmed: 32565481
BMJ. 2005 Jan 1;330(7481):11
pubmed: 15574485
Psychol Med. 2016 Jul;46(9):1923-33
pubmed: 27019301
Lancet Psychiatry. 2019 May;6(5):427-436
pubmed: 30902669
Schizophr Res. 2016 Jan;170(1):217-21
pubmed: 26682958
Psychol Med Monogr Suppl. 1992;20:1-97
pubmed: 1565705